Royal Bank of Canada
SKYE icon

Royal Bank of Canada’s Skye Bioscience SKYE Stock Holding History

Royal Bank of Canada’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Buy
127
+3
+2% +$2 ﹤0.01% 7793
2025
Q4 		$0 Sell
124
-277
-69% -$405 ﹤0.01% 7740
2025
Q3 		$1K Buy
401
+277
+223% +$1.05K ﹤0.01% 7048
2025
Q2 		$0 Sell
124
-1,716
-93% -$3.55K ﹤0.01% 7420
2025
Q1 		$3K Sell
1,840
-1,759
-49% -$4.8K ﹤0.01% 6538
2024
Q4 		$10K Buy
3,599
+1,728
+92% +$7.22K ﹤0.01% 6359
2024
Q3 		$6K Buy
1,871
+162
+9% +$909 ﹤0.01% 6474
2024
Q2 		$14K Buy
+1,709
New +$20.3K ﹤0.01% 6225

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Royal Bank of Canada's SKYE Position: Q1 2026 in Review

Royal Bank of Canada increased its Skye Bioscience (SKYE) stake by 2.4% in Q1 2026, buying an estimated $2 and bringing the position to 127 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7793.

Royal Bank of Canada first reported a position in SKYE in Q2 2024 and has held it in 8 quarters since. The position peaked at $14K in Q2 2024. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Royal Bank of Canada held 127 shares of Skye Bioscience worth $0 as of Q1 2026.
  • Royal Bank of Canada bought 3 Skye Bioscience shares in Q1 2026, an estimated $2.
  • Skye Bioscience made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7793 holding.
  • Royal Bank of Canada first reported a position in Skye Bioscience in Q2 2024 and has held it in 8 quarters since.
  • Royal Bank of Canada's Skye Bioscience position peaked at $14K in Q2 2024.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.